Summary: A research group at Hiroshima University observed a potential new target for chronic pain treatment. Further research using this receptor could lead to new, more effective drugs to use in pain-relieving treatment for chronic pain. Source: Hiroshima University
Conditions that cause chronic pain can be difficult to manage. These include sciatica, cancer and rheumatoid arthritis. Chronic pain mechanisms are complicated, which is one of the reasons why pain management is so difficult, explains Professor Norimitsu Morioka of the Department of Pharmacology, Graduate School of Biomedical & Health Sciences, Hiroshima University. This difficulty decreases the quality of life of patients that, in many cases, can suffer from constant pain with little to no relief. General-purpose pain-relieving medication is often ineffective. Even morphine, possibly the best painkiller according to Assistant Professor Yoki Nakamura, also of the Department of Pharmacology, can fail to inhibit pain in cancer patients.
“Chronic pain is increasing worldwide […] associated with increasing population,” warns Morioka. The increasing number of sufferers of chronic pain means the establishment of new therapeutics is urgent, hence why the results of these types of studies can have important consequences on healthcare for these patients.
Previous research had shown that activating a type of cell receptor (REV-ERBs) that sends chemical signals inside the cell to block the production of certain genes regulates pain-causing and inflammatory molecules inside the body. Such research had shown that a molecule used to ‘turn on’ the REV-ERBs had decreased the production of inflammatory molecules in immune cells but
“Nobody checked the effect of REV-ERBs agonist [stimulator] on nociceptive behaviors [pain reactions] or chronic pain so first we checked the effect of REV-ERBs agonist on chronic pain,” explains Nakamura.
Until now, research has also only looked into one type of pain model at a time. Morioka elaborates that “I think it is not enough to reduce by one target […] I think it is important to cover a lot of molecules mediating chronic pain,” and REV-ERBs seems to be a fitting target “So it is very exciting.”
The research group applied this knowledge to determine if activating the nuclear receptor REV-ERBs in specialized spinal cord cells (astrocytes) results in pain relief in mice. The team treated mice with differing levels of pain sensitivity with molecules that turned on REV-ERBs. The molecules studied can be easily found in today’s pain-relieving drugs according to the team. To test whether there was a notable effect on pain; mice were touched with a filament on their hind paw. Pain was recorded when mice raised their paw away from the filament. Light touches made mice with chronic pain react whereas ‘normal’ mice only moved when the force was increased. Mice with chronic pain when treated with a REV-ERBs stimulator did not react to the lighter touches (depending on the type of chronic pain they had). Through these observations, the research group concluded they did not feel as much pain as the untreated mice with the same type of chronic pain.
Based on these results, the researchers believe that this new target for pain relief could benefit many types of chronic pain sufferers. They plan to perform further research and drug screening experiments to develop new drugs for various types of chronic pain relief.
About this neuroscience research article
Source: Hiroshima University Media Contact: Norifumi Miyokawa – Hiroshima University Image Source: The image is credited to Professor Morioka, Hiroshima University.
Stimulation of nuclear receptor REV-ERBs suppresses production of pronociceptive molecules in cultured spinal astrocytes and ameliorates mechanical hypersensitivity of inflammatory and neuropathic pain of mice
The orphan nuclear receptors REV-ERBα and REV-ERBβ (REV-ERBs) are crucial in the regulation of inflammatory-related gene transcription in astroglioma cells, but their role in nociceptive transduction has yet to be elaborated. Spinal dorsal horn astrocytes contribute to the maintenance of chronic pain. Treatment of cultured spinal astrocytes with specific REV-ERBs agonists SR9009 or GSK4112 significantly prevented lipopolysaccharide (LPS)-induced mRNA upregulation of pronociceptive molecules interleukin-1β (IL-1β) mRNA, interleukin-6 (IL-6) mRNA and matrix metalloprotease-9 (MMP-9) mRNA, but not CCL2 mRNA expression. Treatment with SR9009 also blocked tumor necrosis factor-induced IL-1β mRNA, IL-6 mRNA and MMP-9 mRNA. In addition, treatment with SR9009 significantly blocked LPS-induced upregulation of IL-1β protein, IL-6 protein and MMP-9 activity. The inhibitory effects of SR9009 on LPS-induced expression of pronociceptive molecules were blocked by knockdown of REV-ERBs expression with short interference RNA, confirming that SR9009 exerts its effect through REV-ERBs. Intrathecal LPS treatment in male mice induces hind paw mechanical hypersensitivity, and upregulation of IL-1β mRNA, IL-6 mRNA and glial fibrillary acidic protein (GFAP) expression in spinal dorsal horn. Intrathecal pretreatment of SR9009 prevented the onset of LPS-induced mechanical hypersensitivity, cytokine expression and GFAP expression. Intrathecal injection of SR9009 also ameliorated mechanical hypersensitivity during the maintenance phase of complete Freund’s adjuvant-induced inflammatory pain and partial sciatic nerve ligation-, paclitaxel-, and streptozotocin-induced neuropathy in mice. The current findings suggest that spinal astrocytic REV-ERBs could be critical in the regulation of nociceptive transduction through downregulation of pronociceptive molecule expression. Thus, spinal REV-ERBs could be an effective therapeutic target in the treatment of chronic pain.